These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2190932)

  • 21. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 22. Pulmonary embolism and intravenous high-dose desferrioxamine.
    Cianciulli P
    Haematologica; 1992; 77(4):368-9. PubMed ID: 1427452
    [No Abstract]   [Full Text] [Related]  

  • 23. [The echocardiography in thalassemia major (author's transl)].
    Musumeci S; Schiliro G; Romeo MA; Di Gregorio F; Russo G; Scibilia G
    Pediatr Med Chir; 1981; 3(2-3):219-22. PubMed ID: 6211659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E; Baronciani D; Lucarelli G; Giardini C; Galimberti M; Polchi P; Martinelli F; Baldassarri M; Muretto P
    Bone Marrow Transplant; 1993; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract]   [Full Text] [Related]  

  • 26. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Desferrioxamine B treatment of 4 splenectomized cases of Cooley's anemia].
    Rossi R; Frangini V; Pratesi C
    Riv Clin Pediatr; 1968; 81(5):1002-9. PubMed ID: 5740180
    [No Abstract]   [Full Text] [Related]  

  • 29. Normal serum ferritin levels following prolonged desferrioxamine therapy: Melbourne experience.
    Matthews RN
    Birth Defects Orig Artic Ser; 1988; 23(5B):117-22. PubMed ID: 3390533
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.
    Dutta AK; Ray R; Chandra S; Bhattacharya DK
    J Assoc Physicians India; 1988 Jul; 36(7):463-4. PubMed ID: 3204100
    [No Abstract]   [Full Text] [Related]  

  • 32. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
    Maurer HS; Lloyd-Still JD; Ingrisano C; Gonzalez-Crussi F; Honig GR
    Am J Dis Child; 1988 Mar; 142(3):287-92. PubMed ID: 3344715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose chelation therapy in thalassaemia.
    Lancet; 1984 Feb; 1(8373):373-4. PubMed ID: 6141429
    [No Abstract]   [Full Text] [Related]  

  • 34. Therapy for beta-thalassemia--a paradigm for the treatment of genetic disorders.
    Dover GJ; Valle D
    N Engl J Med; 1994 Sep; 331(9):609-10. PubMed ID: 8047089
    [No Abstract]   [Full Text] [Related]  

  • 35. Chelation therapy and cardiac status in young patients with thalassemia major.
    Roodpeyma S; Alebouye M; Kamali Z
    J Trop Pediatr; 2000 Jun; 46(3):179. PubMed ID: 10893922
    [No Abstract]   [Full Text] [Related]  

  • 36. [Growth velocity in thalassemic children receiving different protocols of chelating therapy].
    Elena MG; Fedele A; Gianino P; Giordanino S; Murru P; Tosi C; Vannelli S
    Minerva Pediatr; 1992; 44(1-2):41-2. PubMed ID: 1552875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management of iron chelation therapy.
    Pippard MJ; Callender ST
    Br J Haematol; 1983 Aug; 54(4):503-7. PubMed ID: 6871105
    [No Abstract]   [Full Text] [Related]  

  • 38. Depletion of excessive liver iron stores with desferrioxamine.
    Cohen A; Martin M; Schwartz E
    Br J Haematol; 1984 Oct; 58(2):369-73. PubMed ID: 6477838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C; Rachmilewitz EA
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.